Results 111 to 120 of about 6,544,440 (152)
Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences. [PDF]
BMC Public Health, 2017 de Vries G, Tsolova S, Anderson LF, Gebhard AC, Heldal E, Hollo V, Cejudo LS, Schmid D, Schreuder B, Varleva T, van der Werf MJ. +10 moreeuropepmc +1 more sourceHIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. [PDF]
Open Forum Infect Dis, 2019 Berenguer J, Calleja JL, Montes ML, Gil Á, Moreno A, Bañares R, Aldámiz-Echevarría T, Albillos A, Téllez MJ, Olveira A, Domínguez L, Fernández I, García-Samaniego J, Polo BA, Álvarez B, Ryan P, Barrio J, Devesa MJ, Benítez L, Santos I, Buey LG, Sanz J, Poves E, Losa JE, Fernández-Rodríguez C, Jarrín I, Calvo MJ, González-García J. +27 moreeuropepmc +1 more sourceCandida guilliermondii Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia. [PDF]
Antimicrob Agents Chemother, 2017 Marcos-Zambrano LJ, Puig-Asensio M, Pérez-García F, Escribano P, Sánchez-Carrillo C, Zaragoza O, Padilla B, Cuenca-Estrella M, Almirante B, Martín-Gómez MT, Muñoz P, Bouza E, Guinea J. +12 moreeuropepmc +1 more sourceCandidemia in non-ICU surgical wards: Comparison with medical wards. [PDF]
PLoS One, 2017 Vena A, Bouza E, Valerio M, Padilla B, Paño-Pardo JR, Fernández-Ruiz M, Díaz Martín A, Salavert M, Mularoni A, Puig-Asensio M, Muñoz P, CANDIPOP Project. +11 moreeuropepmc +1 more sourcePolymerase Chain Reaction Versus Blood Culture to Detect Candida Species in High-Risk Patients with Suspected Invasive Candidiasis: The MICAFEM Study. [PDF]
Infect Dis Ther, 2019 Nieto M, Robles JC, Causse M, Gutiérrez L, Cruz Perez M, Ferrer R, Xercavins M, Herrero E, Sirvent E, Fernández C, Anguita P, Merino P, MICAFEM Study Group, GEIPC (SEIMC) and GTEIS (SEMICYUC). +13 moreeuropepmc +1 more sourceOpen label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children
, 2022 Puga-Gómez R, Ricardo-Delgado Y, Rojas-Iriarte C, Céspedes-Henriquez L, Piedra-Bello M, Vega-Mendoza D, Pestana Pérez N, Paredes-Moreno B, Rodríguez-González M, Valenzuela-Silva C, Sánchez-Ramírez B, Rodríguez-Noda L, Pérez-Nicado R, González-Mugica R, Hernández-García T, Fundora-Barrios T, Echevarría MD, Enriquez-Puertas JM, Infante Hernández Y, Palenzuela-Díaz A, Gato-Orozco E, Chappi-Estévez Y, Francisco-Pérez JC, Martinez MS, Castillo-Quintana IC, Fernandez-Castillo S, Climent-Ruiz Y, Santana-Mederos D, García-Vega Y, Toledo-Romani ME, Doroud D, Biglari A, Valdés-Balbín Y, García-Rivera D, Vérez-Bencomo V, SOBERANA Research Group. +35 moreeuropepmc +1 more sourceAll-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. [PDF]
Hepatology, 2018 Berenguer J, Gil-Martin Á, Jarrin I, Moreno A, Dominguez L, Montes M, Aldámiz-Echevarría T, Téllez MJ, Santos I, Benitez L, Sanz J, Ryan P, Gaspar G, Alvarez B, Losa JE, Torres-Perea R, Barros C, Martin JVS, Arponen S, de Guzmán MT, Monsalvo R, Vegas A, Garcia-Benayas MT, Serrano R, Gotuzzo L, Menendez MA, Belda LM, Malmierca E, Calvo MJ, Cruz-Martos E, González-García JJ. +30 moreeuropepmc +1 more source